Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Acute Lung Injury - Pipeline Review, H2 2013 - New Study Released


Print article Print article
2013-12-22 15:45:20 - New Pharmaceuticals market report from Global Markets Direct: "Acute Lung Injury - Pipeline Review, H2 2013"

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lung Injury. Acute Lung Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of

data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Acute Lung Injury.
* A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Acute Lung Injury pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- www.fastmr.com/prod/755141_acute_lung_injury_pipeline_review_h2_ ..

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: GlaxoSmithKline plc, Quark Pharmaceuticals, Inc., Discovery Laboratories, Inc., Silence Therapeutics plc., Altor BioScience Corporation, Mondobiotech Holding AG, Polyphor Ltd., Implicit Bioscience Limited, KYORIN Pharmaceutical Co., Ltd., Techpool Bio-Pharma Co., LTD., Mayo Clinic, Faron Pharmaceuticals, Ltd., APEPTICO Forschung und Entwicklung GmbH

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Lung Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Lung Injury
Acute Lung Injury Therapeutics under Development by Companies
Acute Lung Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acute Lung Injury Therapeutics - Products under Development by Companies
Acute Lung Injury Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Lung Injury Therapeutics Development
GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Discovery Laboratories, Inc.
Silence Therapeutics plc.
Altor BioScience Corporation
Mondobiotech Holding AG
Polyphor Ltd.
Implicit Bioscience Limited
KYORIN Pharmaceutical Co., Ltd.
Techpool Bio-Pharma Co., LTD.
Mayo Clinic
Faron Pharmaceuticals, Ltd.
APEPTICO Forschung und Entwicklung GmbH
Acute Lung Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
POL-6014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dilmapimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lucinactant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-836 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Respiratory And Inflammatory Diseases Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRP-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atu-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755141&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com